

FORMATO EUROPEO PER
IL CURRICULUM VITAE



PERSONAL DATA:

Nome

Maria Diodoro

Data di nascita

Indirizzo

• Date (da - a)

Degrees

1993: Degree in Medical (summa cum laude), University "La Sapienza", Rome, Italy

1998: Surgical Pathologist (summa cum laude), Univ. "G. D'Annunzio" Chieti.

• Date (da - a)

SCIENTIFIC ACTIVITY

Scientific Career

1993-1994 Fellowship Department of Pathological Anatomy and Histology "S. Liberatore" Hospital, Atri.

1998-1999: Fellowship. Institute of Pathological Anatomy, Medical School, Univ. "G.D'Annunzio" Chieti

1999-2000 Reserch fellow. Institute of Pathological Anatomy, Medical School, Univ. "G.D'Annunzio" Chieti

2000-2001 Assistant Pathologist Department of Pathological Anatomy and Histology. Hospital Teramo

2001-2002 Assistant Pathologist Department of Pathological Anatomy, Medical School "S.Orsola" Bologna.

2002-present: Assistant Pathologist Dept., Regina Elena Cancer Institute, Rome, Italy.

Fields of interest

- Dedicated to gastrointestinal, liver, biliary tract and pancreas. Pathologies both from morphologically point of view and molecular biology (MMR and K-ras genes). Reference Pathologist in the gastrointestinal, liver, biliary tract and pancreas Disease Management Team, Regina Elena Cancer Institute, Rome. Reference Pathologist in the hereditary colon cancer and in hereditary poliposis, Regina Elena Cancer Institute.

Publications:

Publications: 23 papers in international paper reviewed journals

References related to the project (last 5 years) :

1. Bria E, Visca P, Novelli F, Casini B, **Diodoro MG**, Perrone-Donnorso R, Botti C, Sperduti I, Facciolo F, Milella M, Cecere FL, Cognetti F, Mottolese M. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-smallcell lung cancer. *Eur J Surg Oncol.* 2007 Aug 9
2. Benevolo M Mottolese M, Marandino F, Carosi M, **Diodoro MG**, Sentinelli S, Visca P, Rollo F, Mariani L, Vocaturo G, Sindico R, Di Giannuario , Perrone Donnorso R, Vocaturo A. Genotypes HPV Concordance Between Sex Partners: An Italian Case Report . *J Exp Clin Cancer Res.* 2007 26,4:609-613
3. Visca P, Sebastiani V, Botti C, **Diodoro MG**, Lasagni RP, Romagnoli F, Brenna A, De Joannon BC, Donnorso RP, Lombardi G, Alo PL. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma *Anticancer Res.* 2004 Nov-Dec;24(6):4169-73.
4. Torsello A, Garufi C, Cosimelli M, **Diodoro MG**, Zeuli M, Vanni B, Campanella C, Sperduti I, Perrone-Donnorso R, Cognetti F, Terzoli E, Mottolese M. P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance In press *Eur J Cancer* 2008
5. Cosimelli M, Golfieri R., Cagol PP, Carpanese L, Sciuto R., Maini CL, Mancini R, Sperduti I, Pizzi G, **Diodoro MG**, Perrone M, Giampalma E, Angelelli B,

- Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O and Izzo F on behalf of the Italian Society of Locoregional Therapies in Oncology (S.I.T.I.L.O). Multicenter phase II Clinical trial of Yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. *Br J Cancer*. 2010 Jul 27;103(3):324-31. Epub 2010 Jul 13
6. Benevolo M, Mottolese M, Tremante E, Rollo F, **Diodoro MG**, Ercolani C, Sperduti I, Lo Monaco E, Cosimelli M, Giacomini P. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. *J Transl Med*. 2011 Oct 27;9:184.
7. Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensitivity after radioembolization with yttrium-90 resin microspheres. Melucci E, Cosimelli M, Carpanese L, Pizzi G, Izzo F, Fiore F, Golfieri R, Giampalma E, Sperduti I, Ercolani C, Sciuto R, Mancini R, Garufi C, **Diodoro MG**, Mottolese M; Italian Society of Locoregional Therapies in Oncology (S.I.T.I.L.O.). *J Exp Clin Cancer Res*.
8. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, **Diodoro M**, Pescarmona E, Garofalo A, Blandino G. *Cell Death Dis*. 2012 Nov 15;
9. Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis. Grande R, Corsi D, Mancini R, Gemma D, Ciancola F, Sperduti I, Rossi L, Fabbri A, **Diodoro MG**, Ruggeri E, Zampa G, Bianchetti S, Gamucci T. *PLoS One*. 2013 Dec 5;8(12)
10. Early-onset colorectal cancer patients without family history are "at very low risk" for lynch syndrome. Stigliano V, Sanchez-Mete L, Martayan A, **Diodoro M**, Casini B, Sperduti I, Anti M. *J Exp Clin Cancer Res*. 2014 Jan 2;33:
11. Prevalence of HPV infection among clinically healthy Italian males and genotype concordance between stable sexual partners. Lorenzon L, Terrenato I, Donà MG, Ronchetti L, Rollo F, Marandino F, Carosi M, **Diodoro MG**, Sentinelli S, Visca P, Vocaturo G, Bellardini P, Vocaturo A, Benevolo M. *J Clin Virol*. 2014 Jul;60(3):264-9.
12. Detection of phosphorylated insulin receptor in colorectal adenoma and adenocarcinoma: implications for prognosis and clinical outcome. Abbruzzese C, **Diodoro MG**, Sperduti I, Mileo AM, Pattaro G, De Salvo L, Cosimelli M, Perrotti N, Paggi MG. *J Cell Physiol*. 2015 Mar;230(3):562-7
13. Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer. Porru M, Artuso S, Salvati E, Bianco A, Franceschin M, **Diodoro MG**, Passeri D, Orlandi A, Savorani F, D'Incalci M, Biroccio A, Leonetti C.
14. Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Bon G, Loria R, Amoreo CA, Verdina A, Sperduti I, Mastrofrancesco A, Soddu S, **Diodoro MG**, Mottolese M, Todaro M, Stassi G, Milella M, De Maria R, Falcioni R. *Oncotarget*. 2016 Aug 19
15. The pattern of hMENA isoforms is regulated by TGF- β 1 in pancreatic cancer and may predict patient outcome. Melchionna R, Iapicca P, Di Modugno F, Trono P, Sperduti I, Fassan M, Cataldo I, Rusev BC, Lawlor RT, **Diodoro MG**, Milella M, Grazi GL, Bissell MJ, Scarpa A, Nisticò P. *Oncoimmunology*. 2016 Aug 12;5(12)
16. Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine. Parasido EM, Silvestri A, Canzonieri V, Belluco C, **Diodoro MG**, Milione M, Melotti F, De Maria R, Liotta L, Petricoin EF, Pierobon M. *Oncotarget*. 2016 Dec 15.
17. MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer. Canu V, Sacconi A, Lorenzon L, Biagioni F, Sardo FL, **Diodoro MG**, Muti P, Garofalo A, Strano S, D'Errico A, Grazi GL, Cioce M, Blandino G. *Oncotarget*. 2017 Feb 11.
18. DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. Ronchetti L, Melucci E, De Nicola F, Goeman F, Casini B, Sperati F, Pallocca M, Terrenato I, Pizzuti L, Vici P,

- Sergi D, Di Lauro L, Amoreo CA, Gallo E, **Diodoro MG**, Pescarmona E, Vitale I, Barba M, Buglioni S, Mottolose M, Fanciulli M, De Maria R, Maugeri-Saccà M. *Int J Cancer*. 2017 Feb 24
19. A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. Viel A, Bruselles A, Meccia E, Fornasarig M, Quaia M, Canzonieri V, Policicchio E, Urso ED, Agostini M, Genuardi M, Lucci-Cordisco E, Venesio T, Martayan A, **Diodoro MG**, Sanchez-Mete L, Stigliano V, Mazzei F, Grasso F, Giuliani A, Baiocchi M, Maestro R, Giannini G, Tartaglia M, Alexandrov LB, Bignami M. *EBioMedicine*. 2017 Jun;20:39-49. doi:0.1016/j.ebiom.2017.04.022. Epub 2017 Apr 13.
20. tsRNA signatures in cancer. Balatti V, Nigita G, Veneziano D, Drusco A, Stein GS, Messier TL, Farina NH, Lian JB, Tomasello L, Liu CG, Palamarchuk A, Hart JR, Bell C, Carosi M, Pescarmona E, Perracchio L, **Diodoro M**, Russo A, Antenucci A, Visca P, Ciardi A, Harris CC, Vogt PK, Pekarsky Y, Croce CM. *Proc Natl Acad Sci U S A*. 2017 Jul 25;114(30):8071-8076. doi: 10.1073/pnas.1706908114. Epub 2017 Jul 10
21. Tumor Regression Grade After Neoadjuvant Chemoradiation and Surgery for Low Rectal Cancer Evaluated by Multiple Correspondence Analysis: Ten Years as Minimum Follow-up. Mancini R, Pattaro G, **Diodoro MG**, Sperduti I, Garufi C, Stigliano V, Perri P, Grazi GL, Cosimelli M. *Clin Colorectal Cancer*. 2017 Aug 9. pii: S1533-0028(16)30276-6.
22. Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. Melucci E, Casini B, Ronchetti L, Pizzuti L, Sperati F, Pallocca M, De Nicola F, Goeman F, Gallo E, Amoreo CA, Sergi D, Terrenato I, Vici P, Di Lauro L, **Diodoro MG**, Pescarmona E, Barba M, Mazzotta M, Mottolose M, Fanciulli M, Ciliberto G, De Maria R, Buglioni S, Maugeri-Saccà M. *J Transl Med*. 2018 Feb 5;16(1):22. doi: 10.1186/s12967-018-1385-y.
23. EphB2 stem-related and EphA2 progression-related miRNA-based networks in progressive stages of CRC evolution: clinical significance and potential miRNA drivers. De Robertis M, Mazza T, Fusilli C, Loiacono L, Poeta ML, Sanchez M, Massi E, Lamorte G, **Diodoro MG**, Pescarmona E, Signori E, Pesole G, Vescovi AL, Garcia-Foncillas J, Fazio VM. *Mol Cancer*. 2018 Nov 30;17(1):169. doi: 10.1186/s12943-018-0912-z.
24. The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression. Buglioni S, Melucci E, Sperati F, Pallocca M, Terrenato I, De Nicola F, Goeman F, Casini B, Amoreo CA, Gallo E, **Diodoro MG**, Pescarmona E, Vici P, Sergi D, Pizzuti L, Di Lauro L, Mazzotta M, Barba M, Fanciulli M, Vitale I, De Maria R, Ciliberto G, Maugeri-Saccà M. *Oncoimmunology*. 2018 Apr 24;7(8):e1457602. doi: 10.1080/2162402X.2018.1457602. eCollection 2018.
25. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. Pallocca M, Goeman F, De Nicola F, Melucci E, Sperati F, Terrenato I, Pizzuti L, Casini B, Gallo E, Amoreo CA, Vici P, Di Lauro L, Buglioni S, **Diodoro MG**, Pescarmona E, Mazzotta M, Barba M, Fanciulli M, De Maria R, Ciliberto G, Maugeri-Saccà M. *J Transl Med*. 2018 Sep 4;16(1):247. doi: 10.1186/s12967-018-1607-3.
26. Recurrence of gallbladder carcinoma 12 years after laparoscopic cholecystectomy. Carboni F, Federici O, Giofrè M, **Diodoro M**, Valle M. *Clin Res Hepatol Gastroenterol*. 2019 Feb;43(1):e1-e3. doi: 10.1016/j.clinre.2018.08.002. Epub 2018 Aug 30. No abstract available.
27. Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. De Nicola F, Goeman F, Pallocca M, Sperati F, Pizzuti L, Melucci E, Casini B, Amoreo CA, Gallo E, **Diodoro MG**, Buglioni S, Mazzotta M, Vici P, Sergi D, Di Lauro L, Barba M, Pescarmona E, Ciliberto G, De Maria R, Fanciulli M, Maugeri-Saccà M. *Oncogenesis*. 2018 Jul 22;7(7):55. doi: 10.1038/s41389-018-0066-2.

27. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. Chang K, Taggart MW, Reyes-Uribe L, Borrás E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, **Diodoro MG**, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. JAMA Oncol. 2018 Aug 1;4(8):1085-1092. doi: 10.1001/jamaoncol.2018.1482.

28. Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. Melucci E, Casini B, Ronchetti L, Pizzuti L, Sperati F, Pallocca M, De Nicola F, Goeman F, Gallo E, Amoreo CA, Sergi D, Terrenato I, Vici P, Di Lauro L, **Diodoro MG**, Pescarmona E, Barba M, Mazzotta M, Mottolise M, Fanciulli M, Ciliberto G, De Maria R, Buglioni S, Maugeri-Saccà M. J Transl Med. 2018 Feb 5;16(1):22. doi: 10.1186/s12967-018-1385-y.

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Data 10/04/2019